BridgeBio Oncology Therapeutics (BBOT) Notes Payables (2023 - 2026)
BridgeBio Oncology Therapeutics (BBOT) posted Notes Payables of $716000.0 for Q1 2026, up 34.08% sequentially from $534000.0 in Q4 2025, and up 721.26% YoY from $87183.0 in Q1 2025.
BridgeBio Oncology Therapeutics (BBOT) Notes Payables (2023 - 2026) Analysis & Trends
BridgeBio Oncology Therapeutics has reported Notes Payables for 4 years, with the latest figure at $716000.0 in Q1 2026.
- Quarterly Notes Payables rose 721.26% year-over-year to $716000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $716000.0 (up 721.26% YoY) and the FY2025 annual result came in at $534000.0, up 10.56% from the prior year.
- Notes Payables rose to $716000.0 in Q1 2026 per BBOT's latest filing, from $534000.0 in the prior quarter.
- Over five years, Notes Payables peaked at $716000.0 in Q1 2026 and troughed at $70095.0 in Q4 2023.
- A 4-year average of $383976.4 and a median of $483000.0 in 2024 frame the typical range for Notes Payables.
- The sharpest annual moves came in 2025 and 2026: Notes Payables gained 10.56% in 2025, then surged 721.26% in 2026.
- Over 4 years, Notes Payables stood at $70095.0 in 2023, then surged by 589.06% to $483000.0 in 2024, then gained by 10.56% to $534000.0 in 2025, then surged by 34.08% to $716000.0 in 2026.
- According to Business Quant data, Notes Payables over the past three periods registered $716000.0, $534000.0, and $691000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | BridgeBio Oncology Therapeutics | 726.38 Mn | 500.67 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 716,000.00 |
| Dec 31, 2025 | 534,000.00 |
| Sep 30, 2025 | 691,000.00 |
| Jun 30, 2025 | 106,557.00 |
| Mar 31, 2025 | 87,183.00 |
| Dec 31, 2024 | 483,000.00 |
| Dec 31, 2023 | 70,095.00 |